Literature DB >> 11927280

Histone modification: the 'next wave' in cancer therapeutics.

Daphne Chung1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11927280     DOI： 10.1016/s1471-4914(02)02303-1

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


× No keyword cloud information.
  5 in total

1.  RNA-binding ability of PIPPin requires the entire protein.

Authors:  Lavinia Raimondi; Matilde D'Asaro; Patrizia Proia; Tommaso Nastasi; Italia Di Liegro
Journal:  J Cell Mol Med       Date:  2003 Jan-Mar       Impact factor: 5.310

2.  An active site tyrosine residue is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzyme.

Authors:  Kristin Moreth; Daniel Riester; Christian Hildmann; René Hempel; Dennis Wegener; Andreas Schober; Andreas Schwienhorst
Journal:  Biochem J       Date:  2007-02-01       Impact factor: 3.857

Review 3.  Toxoplasma histone acetylation remodelers as novel drug targets.

Authors:  Laura Vanagas; Victoria Jeffers; Silvina S Bogado; Maria C Dalmasso; William J Sullivan; Sergio O Angel
Journal:  Expert Rev Anti Infect Ther       Date:  2012-10       Impact factor: 5.091

Review 4.  Epigenetic effect of chronic stress on dopamine signaling and depression.

Authors:  Sofia Moriam; Mahbub E Sobhani
Journal:  Genet Epigenet       Date:  2013-02-10

5.  Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.

Authors:  Woong Sub Byun; Gyu Ho Lee; Hyeung-Geun Park; Sang Kook Lee
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.